MAPT and tauopathy: Finally, longitudinal studies of plasma NT1-tau (and additional forms of extracellular tau) in other tauopathies and across different disease stages are warranted to further elucidate the diagnostic and prognostic power of tau biomarkers across neurodegenerative diseases.